Presentation (CTI)

OBJECTIVES: To describe the economic outcomes resulting from the implementation of a pharmacotherapeutic management program in oncology patients.
METHODS: A cross-sectional descriptive study was conducted in a cohort of patients diagnosed with cancer who were enrolled in a pharmacotherapeutic management program at an outpatient healthcare institution during the years 2024 and 2025. A systematic follow-up of pharmacological therapy was conducted to identify medication errors and both administrative and clinical inefficiencies, which were subsequently addressed to ensure the appropriateness, adherence, safety, and effectiveness of treatment, as well as to promote the rational use of healthcare resources. A univariate analysis was performed using R Core Team software, version 4.5.0 (2025).
RESULTS: A total of 8571 patients were evaluated, with a mean age of 60 years (SD: 20), of whom 65.2% were female. A total of 3951 errors and inefficiencies were identified, occurring most frequently among patients with breast cancer (43.7%), prostate cancer (8.3%), myeloid leukemia (6.2%), multiple myeloma (5.8%), central nervous system cancer (5.1%), and Kidney cancer (3.5%). The most common issues included suspended treatments that remained active (29.5%), medication authorization errors (27.7%) and duplicate medical orders (15.5%). The most frequently involved drug classes were aromatase inhibitors (21.4%), antimetabolites (7.6%), GnRH analogues (5.9%), tyrosine kinase inhibitors (5.1%), alkylating agents (5.1%), and antiandrogens (5%). The pharmaceutical interventions implemented resulted in an estimated cost savings of USD 5,921,453.19.
CONCLUSIONS: The implementation of pharmacotherapeutic management programs for oncology patients contributes not only to improved clinical outcomes but also to significant economic savings, supporting the sustainability of the healthcare system.